

# Management of non-alcoholic fatty liver disease in diabetes

Gnani N Somasundaram, Noel P Somasundaram, Tahseen A Chowdhury

## ARTICLE POINTS

**1** Non-alcoholic fatty liver disease (NAFLD) is common in people with type 2 diabetes.

**2** Obesity, insulin resistance and dyslipidaemia are all risk factors for NAFLD.

**3** NAFLD can progress to cirrhosis, and poor glycaemic and lipid control can increase the risk of progression.

**4** Higher risk for non-alcoholic steatohepatitis is afforded by older age, obesity, hypertriglyceridaemia, female gender, high AST:ALT ratio and hypertension.

**5** Careful use of statins and insulin sensitisers, even in the presence of raised liver enzymes, may be necessary to reduce vascular and liver disease in patients with NAFLD.

**6** Randomised trials of therapeutic strategies are urgently needed.

## KEY WORDS

- Type 2 diabetes
- NAFLD
- Aetiology
- Treatment

Gnani Somasundaram is Research Fellow, Noel Somasundaram is Visiting Registrar, and Tahseen Chowdhury is Consultant in Diabetes, Department of Diabetes and Metabolism, The Royal London Hospital, London

## Introduction: Clinical scenario

A 41-year-old South Asian man attends your surgery with newly diagnosed type 2 diabetes, diagnosed by the nurse practitioner on the basis of symptoms, and a random plasma glucose of 14.9 mmol/l. You are asked to see him by the nurse practitioner as he has abnormal liver function tests (LFTs), with an aspartate aminotransferase (AST) of 108 units/l (normal range 12–39 units/l), and alanine aminotransferase (ALT) of 97 units/l (normal range <40 units/l). He is obese (BMI 34), hypertensive (blood pressure 165/88 mmHg), microalbuminuric (albumin:creatinine ratio 6.9) and has dyslipidaemia (total cholesterol 6.9 mmol/l, LDL-cholesterol 4.6 mmol/l, fasting triglycerides 3.4 mmol/l, HDL-cholesterol 0.9 mmol/l). An abdominal ultrasound suggests that he has a fatty liver. A standard liver screen, including hepatitis serology, is negative. The nurse practitioner is concerned that pharmacotherapy may exacerbate his liver dysfunction.

- What is the aetiology of fatty liver in people with diabetes?
- Should this patient have a liver biopsy?
- Should he be treated with statins or oral hypoglycaemic agents?

**E**levation of liver enzymes that is unexplained by coexisting common liver diseases is a frequent finding in people with diabetes mellitus. A common cause of such a finding is non-alcoholic fatty liver disease (NAFLD).

Although NAFLD was thought to be a relatively benign condition, data emerging in the past decade suggest that it has the potential to progress to more advanced forms of liver disease, such as non-alcoholic steatohepatitis (NASH) (Diehl et al, 1988; Powell et al, 1990; Bacon et al, 1994; Matteoni et al, 1999), fibrosis, cirrhosis (Poonawala et al, 2000) or hepatocellular carcinoma (Bugianesi et al, 2002).

NAFLD encompasses a spectrum of conditions, ranging from steatosis (fatty liver) through to steatohepatitis and cirrhosis. Previous studies have suggested that simple steatosis is generally benign, while patients with NASH have a higher propensity to cirrhosis (Teli et al, 1995; Matteoni et al, 1999). Progression of liver damage has, however, been observed even in mild NAFLD, and any amount of fat in the hepatocytes may sensitise the liver to injury from other causes.

A significant proportion of patients previously thought to have cryptogenic

cirrhosis share many of the clinical and demographic features of NAFLD, suggesting that the aetiology of their cirrhosis may be unrecognised NAFLD (Powell et al, 1990; Cadwell et al, 1999; Poonawala et al, 2000).

## Aetiology of NAFLD

The main associations of NAFLD are obesity, type 2 diabetes, dyslipidaemia and insulin resistance, all of which are cardinal features of the metabolic syndrome (Marchesini et al, 2003). A number of studies suggest that NAFLD should be considered the hepatic manifestation of the metabolic syndrome.

Obesity, diabetes and hypertriglyceridaemia are 5.3-fold, 4.0-fold, and 6.7-fold more common, respectively, in people with severe steatosis on histology, compared with controls (Angelico et al, 2003), and the presence of the metabolic syndrome carried a high risk of NASH in subjects with NAFLD (Marchesini et al, 2003).

Prevalence of NAFLD in patients with obesity or type 2 diabetes can be as high as 80–90% (Silverman et al, 1989, 1990; Angelico et al, 2003), although large studies are not available. In one study, liver biopsy of people with diabetes, obesity or dyslipidaemia found

**PAGE POINTS**

**1** Prevalence of NAFLD in people with obesity or type 2 diabetes can be as high as 80–90%.

**2** The available data on NAFLD in people with diabetes suggest that these patients must be carefully investigated and monitored.

**3** NAFLD should be suspected in a patient with liver disease in whom other common causes, such as alcohol, viral infection, drugs, and autoimmune, genetic or metabolic disorders have been excluded.

**4** Recent studies suggest that NAFLD is the most likely histological diagnosis in the increasing number of people presenting with persistently elevated transaminases.

**Table 1. Predictors of NASH and advanced fibrosis on index liver biopsy**

- Age >45 years
- Obesity (BMI >28)
- Type 2 diabetes
- Hypertriglyceridaemia
- Female gender
- High AST and ALT
- AST:ALT ratio >1
- Hypertension

ALT = alanine aminotransferase; AST = aspartate aminotransferase; NASH = non-alcoholic steatohepatitis

an 82% prevalence of NASH (Marchenisi et al, 2004).

An Italian population-based study of people with type 2 diabetes found that standardised mortality rates for cirrhosis were 2.5 times higher than expected (Younossi et al, 2004). Other studies that looked at the outcome of people with NAFLD and diabetes also report a more aggressive form of disease and higher overall mortality and mortality related to liver disease (Sargin et al, 2003). The available data on NAFLD in people with diabetes suggest that these patients must be carefully investigated and monitored.

Oxidative stress has been postulated as an aetiological factor for the development of NAFLD. One suggested mechanism, which links steatosis to necro-inflammation and fibrosis, is lipid peroxidation. Induction of cytochrome P4502E1 (CYP2E1) by its substrates, such as fatty acids, is well recognised (Robertson et al, 2001). This leads to the production of free radicals, resulting in lipid peroxidation, mitochondrial damage and liver injury. CYP2E1-mediated generation of oxidative stress-related parameters and diminished antioxidant capacity have been demonstrated in the presence of fatty liver (Albano et al, 1996).

A number of genetic loci have been linked with NAFLD. These include genes that contribute to insulin resistance, pro-fibrotic polymorphisms promoting fibrosis in the presence of steatosis, and polymorphism of CYP2E1 (Dixon et al, 2003). All studies have been relatively small and inconclusive. Mutations in the genes encoding peroxisome proliferator-activated receptor- $\gamma$  (PPAR- $\gamma$ ) and other regulators of the insulin signalling pathway have been identified in partial lipodystrophy (Agarwal and Garg, 2002), but have yet to be examined in NAFLD. It seems probable that if a genetic component is important in the pathogenesis of the condition, it is likely to be polygenic – similar to the metabolic syndrome and type 2 diabetes.

It has been suggested that excessive iron deposition may contribute to NAFLD. One study found elevated serum ferritin levels and increased transferrin saturation in people with NASH. Hepatic iron index and hepatic iron levels are usually in the normal range (Younossi et al, 1999), but studies

that looked at the possibility of hepatic iron overload as an aetiological factor have shown that hepatic iron deposition and the HFE gene of familial haemochromatosis are not necessary for the development of NAFLD (Bugianesi et al, 2004).

**Clinical diagnosis of NAFLD**

NAFLD should be suspected in a patient with liver disease in whom other common causes, such as alcohol, viral infection, drugs, and autoimmune, genetic or metabolic disorders have been excluded. Careful exclusion of alcohol as an aetiological factor is required, and it has been suggested that a cut-off level of 14–28 units per week is needed to differentiate between alcohol-related and NAFLD (Brent et al, 2003).

Recent studies suggest that NAFLD is the most likely histological diagnosis in the increasing number of people presenting with persistently elevated transaminases (Berasain et al, 2000; Skelly et al, 2001).

NAFLD is often detected during routine evaluation of liver enzymes and imaging for unrelated conditions. Liver transaminases may be normal, or only marginally elevated (Mofrad et al, 2003). The gold standard for diagnosis of NAFLD is liver biopsy. There is poor correlation between biochemistry, ultrasonography and histology, and the entire histological spectrum of NAFLD can be seen in individuals with normal transaminase values (Mofrad et al, 2003). In addition, normal liver enzyme levels do not guarantee freedom from underlying steatohepatitis and advanced cirrhosis. There is thus a clinical dilemma of whether to subject the patient to an invasive procedure, which carries some risk, in order to diagnose and stage a disease in apparently asymptomatic patients.

A number of studies have addressed clinical predictors of more advanced histology on the initial diagnostic biopsy (Table 1). Older age, increasing obesity, type 2 diabetes and hypertriglyceridaemia appear to be the strongest independent predictors of more advanced disease (Angulo et al, 1999; Dixon et al, 2001).

Other factors identified as predictors of advanced disease include female gender, impaired glucose tolerance, insulin resistance, high fasting C-peptide, hypertension, elevation of AST or ALT, and an AST:ALT ratio of >1.0.

These factors are generally used to identify patients in whom liver biopsy may provide the most prognostic information.

**Management strategies for NAFLD (Table 2)**

Treatment of NAFLD in people with diabetes is a relatively evidence-poor area, and large randomised trials are needed.

**Lifestyle change**

This is aimed at obesity, diabetes and dyslipidaemia. In people with diabetes, good metabolic control is always recommended, but not always effective in reversing NAFLD. Weight reduction can result in improvement in liver biochemistry and the degree of steatosis (Erikson et al, 1986; Palmer and Shaffner, 1990; Ueno et al, 1997).

It seems sensible to limit alcohol intake, as one study has shown that reduced alcohol intake protects against the development of NASH in people with NAFLD (Angulo et al, 1999). Complete abstinence is required if significant fibrosis is present (Brent et al, 2003).

**Lipid-lowering agents**

Lipid-lowering agents such as gemfibrozil (Basaranoglu et al, 1999), bezafibrate (Saibara et al, 1999), and atorvastatin (Horlander et al, 2001; Nair and Wiseman, 2002) have been tried in patients with NAFLD, with some promising results, such as improved liver enzymes and biopsy findings, in a few small trials. However, the effects of various lipid-lowering agents need to be established in larger studies.

Careful monitoring of liver function is required in this setting, but raised transaminases should not be seen as a contraindication to lipid-lowering therapy in NAFLD, as the benefits of cardiovascular risk reduction considerably outweigh the risks of hepatic dysfunction.

**Oral hypoglycaemic agents**

Metformin has been studied in the treatment of NAFLD animal models and in a limited number of patients with diabetes and NAFLD, with promising results (Coyle et al, 1999; Marchesini et al, 2001; Urso and Visco-Comandini, 2002). Metformin also down-regulates hepatic gluconeogenesis, and may

have beneficial effects through inhibition of hepatic expression of tumour necrosis factor alpha (TNF- $\alpha$ ) and TNF-inducible factors that promote lipid accumulation and ATP depletion in the liver (Lin et al, 2000; Zhou et al, 2001). With a relatively safe side-effect profile, metformin may prove useful in people with NAFLD and pre-diabetes, insulin resistance and metabolic syndrome.

Thiazolidinediones have been used in small studies of NAFLD. These agents can improve liver enzymes as well as histological findings (Acosta et al, 2001; Caldwell et al, 2001; Azuma et al, 2002; Neuschwander-Tetri et al, 2002; Sanyal et al, 2002). Improved insulin sensitivity, reduced central adiposity and reduced TNF- $\alpha$  are likely to contribute to this effect (Galli et al, 2002).

The *British National Formulary 47* states that thiazolidinediones are contraindicated in patients with 'hepatic impairment'. Considerable care should therefore be exercised when using these drugs in NAFLD. Nevertheless, judicious use as second-line therapy to metformin may be considered in patients with diabetes and NAFLD and poor glycaemic control.

**Outcome of clinical scenario**

The case scenario presented in the introduction to this article describes a patient at relatively high risk of non-alcoholic steatohepatitis as a result of being obese, hypertensive, hypertriglyceridaemic and having an AST:ALT ratio >1.

He was referred for liver biopsy, which showed only fatty change and no sign of hepatitis. He was treated with a statin, metformin and antihypertensive therapy, following which his LFTs improved, as did his glycaemia, blood pressure and dyslipidaemia. ■

Acosta RC, Molina EG, O'Brien CB et al (2001) The use of pioglitazone in nonalcoholic steatohepatitis (Abstract). *Gastroenterology* **120**: A546

Agarwal AK, Garg A (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. *Journal of Clinical Endocrinology and Metabolism* **87**: 408-11

Albano E, Clot P, Morimoto M, Tomasi A, Ingelman-Sundberg M, French SW (1996) Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. *Hepatology* **23**: 155-63

Angelico F, Del Ben M, Conti R et al (2003) Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. *Journal of Gastroenterology and Hepatology* **18**: 588-94

Angulo P, Keach JC, Batts KP et al (1999) Independent predictors of liver fibrosis in patients with non-

**PAGE POINTS**

**1** Treatment of NAFLD in people with diabetes is a relatively evidence-poor area, and large randomised trials are needed.

**2** Lipid-lowering agents have been tried in small studies of patients with NAFLD, with some promising results.

**3** With a relatively safe side-effect profile, metformin may prove useful in people with NAFLD and pre-diabetes, insulin resistance and metabolic syndrome.

**Table 2. Potential treatment modalities for non-alcoholic fatty liver disease**

- **Lifestyle changes**
  - Exercise
  - Diet
  - Gradual weight reduction
- **Cytoprotective agents**
  - Ursodeoxycholic acid
- **Antioxidants**
  - Vitamin E
  - Betaine
  - N-acetylcysteine
- **Lipid-lowering drugs**
  - Gemfibrozil
  - Bezafibrate
  - Atorvastatin
- **Oral hypoglycaemics**
  - Metformin
  - Thiazolidinediones

- alcoholic steatohepatitis. *Hepatology* **30**: 1356–62
- Azuma T, Tomita K, Kato S et al (2002) A pilot study of a thiazolidinedione, pioglitazone, in non-alcoholic steatohepatitis (Abstract). *Hepatology* **36**: A406
- Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994) Non-alcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* **107**: 1103–09
- Basaranoglu M, Acbay O, Sonsuz A (1999) A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (Letter). *Hepatology* **31**: 384
- Berasain C, Beles M, Panizo A et al (2000) Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. *Gut* **47**: 429–35
- Brent A, Neuschwander-Tetri, Caldwell SH (2003) Non-alcoholic steatohepatitis: summary of an AASLD single topic conference. *Hepatology* **37**: 1202–19
- Bugianesi E, Leone N, Vanni E et al (2002) Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* **123**: 134–40
- Bugianesi E, Manzini P, D'Antico S et al (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. *Hepatology* **39**: 179–87
- Cadwell SH, Oelsner DH, Jezzoni JC, Hesenheide EE, Battle EH, Driscoll CJ (1999) Cryptogenic cirrhosis: clinical characterisation and risk factors for underlying disease. *Hepatology* **29**: 664–70
- Caldwell SH, Hesenheide EE, Redick JA et al (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. *American Journal of Gastroenterology* **96**: 519–25
- Coyle WJ, Delaney N, Yoshihashi A, Lawson P (1999) Metformin treatment in patients with non-alcoholic steatohepatitis normalises LFTs and improves histology (Abstract). *Gastroenterology* **116**: A1198
- Diehl AM, Goodman Z, Ishak KG (1988) Alcohol-like liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury. *Gastroenterology* **95**: 1056–62
- Dixon JB, Bhathal PS, O'Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* **121**: 91–100
- Dixon JB, Bhathal PS, Jonsson JR, Dixon AF, Powell EE, O'Brien PE (2003) Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. *Hepatology* **39**: 967–71
- Eriksson S, Eriksson KF, Bondesson L (1986) Nonalcoholic steatohepatitis in obesity: a reversible condition. *Acta Medica Scandinavica* **220**: 83–88
- Galli A, Crabb DW, Ceni E et al (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. *Gastroenterology* **122**: 1924–40
- Horlander JC, Kwo PY, Cummings OW, Koukoulis G (2001) Atorvastatin for the treatment of NASH (Abstract). *Gastroenterology* **120**: A544
- Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty disease in obese, leptin-deficient mice. *Nature Medicine* **26**: 998–1003
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in non-alcoholic steatohepatitis (Letter). *Lancet* **358**: 893–94
- Marchesini G, Bugianesi E, Forlani G et al (2003) Non-alcoholic fatty liver and the metabolic syndrome. *Hepatology* **37**: 917–23
- Marchesini G, Bugianesi E, Forlani G et al (2004) Non-alcoholic steatohepatitis in patients cared in metabolic units. *Diabetes Research and Clinical Practice* **63**: 143–51
- Matteoni CA, Younossi ZM, Garlic T, Bavaria N, Liu YC, McCullough AJ (1999) Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* **116**: 1413–19
- Mofrad P, Contos MJ, Haque M et al (2003) Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. *Hepatology* **37**: 1286–92
- Nair S, Wiseman M (2002) HMG-CoA reductase inhibitors in non-alcoholic fatty liver disease: is their potential hepatotoxicity an issue in these patients? A case control study based on histology (Abstract). *Hepatology* **36**: 409A
- Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR, Hampton K (2002) Histological improvement in NASH following increased insulin sensitivity with PPAR-gamma ligand rosiglitazone for 48 weeks (Abstract). *Hepatology* **36**: 379A
- Palmer M, Shaffner F (1990) Effect of weight reduction on hepatic abnormalities in overweight patients. *Gastroenterology* **99**: 1408–13
- Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of non-alcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. *Hepatology* **11**: 74–80
- Poonawala A, Nair SP, Thuluvath PJ (2000) Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case control study. *Hepatology* **32**: 689–92
- Robertson G, Leclercq I, Farrell GC (2001) Non-alcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. *American Journal of Physiology* **281**: G1135–39
- Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H (1999) Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis (Letter). *Lancet* **353**: 1802
- Sanyal AJ, Contos MJ, Sargeant RT, Luketic VA, Sterling RK, Shiffman ML (2002) A randomised controlled pilot study of pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis (Abstract). *Hepatology* **36**: A382
- Sargin M, Uygur-Bayramicli O, Sargin H, Orbay E, Yayla A (2003) Association of non-alcoholic fatty liver disease with insulin resistance: OGTT indicated in non-alcoholic fatty liver disease? *Journal of Clinical Gastroenterology* **37**: 399–402
- Silverman JF, Pories WJ, Caro JF (1989) Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. *Pathology Annual* **24**: 275–302
- Silverman JF, O'Brien KF, Long S et al (1990) Liver pathology in morbidly obese patients with and without diabetes. *American Journal of Gastroenterology* **85**: 1349–55
- Skelly MM, James PD, Ryder SD (2001) Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. *Hepatology* **35**: 195–99
- Teli MR, James OF, Burt AD et al (1995) The natural history of non-alcoholic fatty liver: a follow-up study. *Hepatology* **22**: 1714–19
- Ueno T, Sugswara H, Sujaku K et al (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *Hepatology* **27**: 103–07
- Urso R, Visco-Comandini U (2002) Metformin in non-alcoholic steatohepatitis (Letter). *Lancet* **359**: 355–56
- Younossi ZM, Gramlich T, Bacon BR et al (1999) Hepatic iron and non-alcoholic fatty liver disease. *Hepatology* **30**: 847–50
- Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ (2004) Non-alcoholic fatty liver disease in patients with type 2 diabetes. *Clinical Gastroenterology and Hepatology* **2**: 262–65
- Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. *The Journal of Clinical Investigation* **108**: 1167–74